English 
Japanese 
We are honored to announce that we’ve been chosen as a finalist for the prestigious Biotech Company of the Year at the CITELINE Japan Award 2024, which celebrates exceptional achievements and groundbreaking innovation in the pharmaceutical and biotech industries. Read More
Archives: News
Notice of Article Published in the Nikkei
Prism BioLab in the Spotlight for Drug Discovery, Recognized by Major Pharma https://www.nikkei.com/article/DGXZQOUC06CAK0W4A900C2000000/
Eisai to Present E7386, co-created by PRISM BioLab and Eisai, at the ESMO (European Society for Medical Oncology) Annual Meeting
TOKYO, Japan, 9 September 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the interim analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate ( “lenvatinib”) will be presented...
PRISM BioLab opens a business office in Tokyo
We are pleased to announce the establishment of PRISM BioLab Co., Ltd. Tokyo office. The office was officially opened on September 2, 2024 and will serve as a base for our business and administrative functions, for enhanced communications with our investors and partners, and to enable more effective business decisions. We sincerely appreciate the continued...
Announcement of Initial Listing on Tokyo Stock Exchange Growth Market
PRISM BioLab Corporation is pleased to announce its initial listing on the Tokyo Stock Exchange Growth Market today. We would like to take this opportunity to express our sincere gratitude to all our stakeholders for their unwavering support and cooperation. For more details regarding our new listing, please visit the Tokyo Stock Exchange website. https://www.jpx.co.jp/listing/stocks/new/index.html...
Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange
PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing of our shares on the Growth Market of the Tokyo Stock Exchange. Read Full Press Release-Japanese Text Only
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
TOKYO, Japan, 25 Apr 2024: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and licensing agreement with ONO PHARMACEUTICAL CO., LTD. . Read Full Press Release
Announcement of setting the record date for stock split
Announcement of setting the record date for stock split（pdf）
PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of...
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and Company. Read Full Press Release